Delix Therapeutics (Series A+)

Funding Details
Awarder
Gaingels
Date Award
May 24, 2024
Vertical
Healthcare and Biotech
Funding URL
View Funding Page
Valuation
$250,000,000

Company Info
Founders
Mark Rus
Company Description
Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, Delix is building a company to find solutions for CNS-related diseases.. Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
Market
Healthcare & Wellness
Coinvestors
ARTIS Ventures

Links
Back to Home Back to Healthcare and Biotech Deals View Funding Announcement